Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04355494
Expanded Access Status : No longer available
First Posted : April 21, 2020
Last Update Posted : March 9, 2021
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
This protocol provides access to eculizumab treatment for participants with severe COVID-19.

Condition or disease Intervention/treatment
COVID-19 Pneumonia, Viral Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) Biological: eculizumab

Detailed Description:

This is an open label, multicenter, Expanded Access Program (EAP) to allow participants with a confirmed diagnosis of SARS-CoV-2 infection, and a clinical presentation consistent with COVID-19 severe pneumonia, acute lung injury, or ARDS to be treated with eculizumab. Participants admitted to a designated hospital facility who qualify for emergency treatment will be administered eculizumab up to 7 times during their treatment course (5 mandatory doses and up to 2 optional doses, per Investigator assessment).

The EAP consists of a Screening Period of up to 7 days, a 4-week Treatment Period, a final in-hospital assessment on Day 29 or day of discharge, whichever occurs first, and 3 monthly safety follow up visits (to be conducted as a telephone call if the participant has been discharged from the hospital or an in-person visit if the participant is still hospitalized).

For each participant, the total duration of the program is anticipated to be 4.5 months.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Intermediate-size Population
Official Title: SOLIRIS® (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID 19) - An Expanded Access Program for Hospital-based Emergency Treatment

Intervention Details:
  • Biological: eculizumab
    Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)
    Other Name: Soliris

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. Males or females ≥ 18 years of age and ≥ 40 kg at the time of providing informed consent.
  2. Confirmed diagnosis of SARS-CoV-2 infection presenting as severe COVID-19 requiring hospitalization
  3. Symptomatic, bilateral pulmonary infiltrates confirmed by CT or X-ray at Screening or within the 7 days prior to Screening
  4. Severe pneumonia, acute lung injury, or ARDS requiring oxygen supplementation

Exclusion Criteria:

  1. Confirmed diagnosis of SARS-CoV-2 infection presenting as mild to moderate COVID-19, even if the participant is hospitalized
  2. Participant is not expected to survive more than 24 hours
  3. Participant has an unresolved Neisseria meningitidis infection
  4. Hypersensitivity to murine proteins or to one of the excipients of Soliris

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04355494

Layout table for location information
United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
United States, Massachusetts
Boston Medical Center
Boston, Massachusetts, United States, 02118
Newton-Wellesley Hospital
Newton, Massachusetts, United States, 02462
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, New Jersey
Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States, 08901
United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
United States, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43210
Hôpital Henri Mondor
Creteil, France, 94000
Hôpital Garches Raymond Poincaré
Garches, France, 92380
Hôpital de Bicêtre
Le Kremlin Bicêtre, France, 94275
Hôpital Saint Louis
Paris, France, 75010
Hôpital Paul Brousse
Villejuif, France, 94800
Sponsors and Collaborators
Alexion Pharmaceuticals
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals Identifier: NCT04355494    
Other Study ID Numbers: ECU-COV-401
First Posted: April 21, 2020    Key Record Dates
Last Update Posted: March 9, 2021
Last Verified: March 2021
Keywords provided by Alexion Pharmaceuticals:
acute lung injury
acute respiratory distress syndrome
antibodies, monoclonal, humanized
complement inhibition
emergency treatment
expanded access program
severe acute respiratory syndrome
severe acute respiratory syndrome coronavirus 2
severe pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Viral
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Lung Injury
Pathologic Processes
Respiratory Tract Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Thoracic Injuries
Wounds and Injuries
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs